Regeneron Pharmaceuticals stock slumped on Friday after two late-stage trials for an experimental drug co-developed with ...

By Sriparna Roy (Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of ...

Joe Walsh is the first Alzheimer's patient to be treated with an experimental nasal spray designed to reduce inflammation in ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for ...

Learn how a new genetic therapy could transform treatment for rare ALS—keep reading for remarkable patient outcomes.

An experimental drug known as ulefnersen has shown remarkable efficacy in treating a rare, aggressive form of ALS ...

An experimental drug developed at Duke University School of Medicine could offer powerful pain relief without the dangerous ...

When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he ...

Typically, the goal of ALS treatments is to slow the disease or halt progression. But new data from the antisense oligonucleotide (ASO) jacifusen for FUS-ALS show that two patients went beyond the ...

US FDA grants fast track designation to EDDC’s antibody-drug conjugate EBC-129 to treat pancreatic ductal adenocarcinoma: Singapore Thursday, May 29, 2025, 12:00 Hrs [IST] The E ...

Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung ...